• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Monoclonal antibodies for treating osteoporosis
【24h】

Monoclonal antibodies for treating osteoporosis

机译：用于治疗骨质疏松症的单克隆抗体

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Osteoporosis is the most widespread skeletal disease requiring innovative therapeutic strategies for its management. The understanding of receptor activator of nuclear factor kappa-B ligand (RANKL) and sclerostins role in bone cell biology is completely changing the therapeutic landscape. RANKL supports osteoclast formation and activity and is mainly produced by cells of osteoblastic lineage. Sclerostin, an antagonist of the Wnt pathway, has a key role in bone formation and is mainly secreted by osteocytes. High levels of RANKL and sclerostin have been detected in osteoporosis, leading to the production of antibodies able to neutralize their activity. Areas covered: In this review, the authors give an overview and discuss the literature and data on denosumab and romosozumab to treat osteoporosis. Clinical studies indicate that long-term treatment with denosumab causes a continuous increase in bone mineral density with low incidence of adverse effects. Romosozumab treatment gives increases bone formation and improves bone mineral density (BMD) though further studies are needed to better evaluate the adverse effects. Expert opinion: Denosumab and romosozumab show promise in the treatment of osteoporosis. Furthermore, their different mechanisms of action compared to existing anti-osteoporotic drugs may permit alternative strategies for osteoporosis treatment down the line.
机译：介绍：骨质疏松症是最普遍的骨骼疾病，需要进行创新治疗策略的管理。理解核因子Kappa-B配体（RANKL）和骨细胞生物学中的菌毒素作用的理解是完全改变治疗景观。 RANKL支持骨果岭形成和活性，主要由骨细胞谱系的细胞产生。 Wnt途径的拮抗剂巩膜蛋白在骨形成中具有关键作用，主要由骨细胞分泌。在骨质疏松症中检测到高水平的RANKL和SCLEROSTIN，导致能够中和活性的抗体。所涵盖的区域：在本次审查中，作者概述并讨论了Denosumab和RomoSozumab的文献和数据，以治疗骨质疏松症。临床研究表明，具有Denosumab的长期治疗导致骨矿物质密度的连续增加，不良反应的发生率低。罗马窦治疗使骨形成增加并改善骨矿物密度（BMD），尽管需要进一步研究以更好地评估不良反应。专家意见：Denosumab和RomoSozumab在治疗骨质疏松症的情况下表达了承诺。此外，与现有的抗骨质疏松药物相比，它们不同的作用机制可能允许骨质疏松症治疗的替代策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号